BC Week In Review | Dec 1, 2017
Clinical News

Critical Outcomes expands Phase I COTI-2 study to HNSCC

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF) expanded an open-label, U.S. Phase I trial evaluating oral COTI-2 in gynecological malignancies to include up to 36 patients with squamous cell carcinoma of the head and neck (SCCHN)...
BC Innovations | Apr 13, 2017
Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...
BC Week In Review | Feb 22, 2016
Clinical News

COTI-2: Phase I started

Critical Outcome began an open-label, U.S. Phase I trial to evaluate oral COTI-2 in up to 46 patients with platinum-resistant, recurrent ovarian, endometrial or cervical cancer. Patients will receive COTI-2 for 5 consecutive days followed...
BC Week In Review | Oct 13, 2014
Company News

Critical Outcome Technologies cancer news

Critical Outcome's board approved a shareholder rights plan to protect shareholders in the event of an unsolicited takeover bid. Under the plan, shareholders on record on the effective date will receive one right for each...
BC Week In Review | Jun 30, 2014
Clinical News

COTI-2 regulatory update

FDA granted Orphan Drug designation to Critical Outcome’s COTI-2 to treat ovarian cancer. The company said it plans to start a Phase I trial of the small molecule inhibitor of protein kinase B (PKB; PKBA...
BC Week In Review | Mar 3, 2014
Company News

Critical Outcome Technologies, Portage Biotech deal

The companies signed a non-binding letter of intent to form a JV to develop Critical Outcome's preclinical cancer compound COTI-2 . The JV would have an exclusive license to develop COTI-2 from the start of final...
BC Week In Review | Aug 22, 2011
Clinical News

Critical Outcome Technologies preclinical data

In a mouse model of ovarian cancer, 40 mg/kg IV COTI-2 daily for 5 days/week produced a significantly greater complete remission (CR) rate vs. vehicle-treated controls (30% vs. 0%, p<0.01). However, 20 mg/kg IV COTI-2...
BC Week In Review | Apr 12, 2010
Clinical News

Critical Outcome Technologies preclinical data

In an animal model of breast cancer, 200 mg/kg oral COTI-2 daily for 5 days prior to tumor implantation and 5 days/week thereafter inhibited tumor growth by 78% at day 38 vs. vehicle control (p<0.001)....
BC Week In Review | Mar 29, 2010
Company News

Critical Outcome Technologies cancer news

Critical Outcome hired BioStrategy Management Inc. to assist the biotech with strategic initiatives related to financing, business development and R&D. Critical Outcome's COTI-2 is in preclinical testing to treat cancer. COTI-2 is a small molecule...
BC Week In Review | Jan 25, 2010
Clinical News

Critical Outcome Technologies preclinical data

In an animal model of human pancreatic cancer, oral COTI-2 plus Abraxane nab-paclitaxel produced complete tumor regressions and was significantly more "effective" than Abraxane alone at day 28. COTI-2 alone and in combination with Abraxane...
Items per page:
1 - 10 of 13